Although BRAF inhibitors have been practice-changing in the treatment of BRAF-mutated melanoma, they demonstrated a surprising and striking lack of efficacy as single agents in patients with colorectal cancer harboring BRAFV600E mutations [75,76]. This evidence concerns the gene BRAF and melanoma.